Search
Dexamethasone Treatment Options
A collection of 1465 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
445 - 456 of 1465
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Completed
Primary Objective:
Phase 1:
To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
Phase 2 (stage 1):
To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as single agent or in combination with dexamethasone.
Phase 2 (stage 2):
To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the selec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Mayo Clinic Site Number : 840003, Scottsdale, Arizona +58 locations
Conditions: Hematological Malignancy
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Active Not Recruiting
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Loyola University Medical Center, Maywood, Illinois +4 locations
Conditions: Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
Pharmacokinetics of Aqueous Dexamethasone
Completed
The study is being done to measure the absorption of the DEXTENZA implant and inflammation concentration levels in the eye.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
10/18/2024
Locations: Bucci Laser Vision, Wilkes-Barre, Pennsylvania
Conditions: Pharmacokinetics, Aqueous Dexamethasone, Inflammatory Cytokine Response
Particulate Vs. Non-Particulate Steroid for Sacroiliac Joint Injection
Recruiting
This study will compare two different corticosteroids (dexamethasone and methylprednisolone) for use in sacroiliac joint injections to treat SI joint pain.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/18/2024
Locations: University of New Mexico Hospital, Albuquerque, New Mexico
Conditions: Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Terminated
The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose exploration part to identify the RP2D of AMG 701 in combination with pomalidomide, with and without dexamethasone... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Mayo Clinic - Arizona, Scottsdale, Arizona +33 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Active Not Recruiting
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Advanced Vision Care, Los Angeles, California
Conditions: Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
Withdrawn
Compare hearing outcomes between treatment with dexamethasone versus prednisone in participants who have been diagnosed with unilateral SSNHL (sudden sensorineural hearing loss).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/10/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Sudden Sensorineural Hearing Loss (SSNHL)
High Dose Carfilzomib for Newly Diagnosed Myeloma
Completed
The purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients. In addition, the study is designed to test the amount of remaining myeloma cells in the body after treatment with higher carfilzomib doses which is known as minimal residual disease (MRD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +5 locations
Conditions: Multiple Myeloma
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Active Not Recruiting
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result in more patients achieving minimal residual disease (MRD)-negative status, relative to the standard of care. Consolidation therapy will be administered only to those patients with MRD-positive status after induction therapy.
This is a study based o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan +3 locations
Conditions: Multiple Myeloma
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
Active Not Recruiting
This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/07/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Active Not Recruiting
The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California +15 locations
Conditions: Relapsed or Refractory Large B-cell Lymphoma
ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Recruiting
Multiple myeloma (MM) is a malignancy characterized by uncontrolled proliferation of plasma cells for which there is an urgent and unmet need to develop new, effective therapeutics. Onconova Therapeutics has developed a first-in-class oral inhibitor of CDK4 and ARK5 ON 123300 (NARAZACICLIB) which shows potent anti-myeloma activity in vitro and in vivo in preclinical models, and is undergoing evaluation in Phase 1-2 trials worldwide.
In this study, the researchers will test the safety and prelim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Mount Sinai Health System, New York, New York
Conditions: Relapsed and/or Refractory Multiple Myeloma
445 - 456 of 1465